NASDAQ:BIIB Biogen (BIIB) Stock Price, News & Analysis $199.95 -6.04 (-2.93%) Closing price 04:00 PM EasternExtended Trading$200.22 +0.28 (+0.14%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biogen Stock (NASDAQ:BIIB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Biogen alerts:Sign Up Key Stats Today's Range$199.62▼$205.6550-Day Range$187.80▼$216.6352-Week Range$121.05▼$219.72Volume962,712 shsAverage Volume1.54 million shsMarket Capitalization$29.52 billionP/E Ratio21.45Dividend YieldN/APrice Target$220.04Consensus RatingModerate Buy Company Overview Biogen Inc. is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets. The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders. Biogen has also been active in the Alzheimer's field through collaborations with Eisai, bringing antibodies targeting amyloid pathology to market. In addition, Biogen has worked with partners on treatments for spinal muscular atrophy and other rare diseases, reflecting a mix of proprietary development and co-commercialization arrangements. Biogen invests heavily in research and development, maintaining clinical-stage programs across a range of neuroscience indications and pursuing both small- and large-molecule approaches. The company operates through a combination of internal discovery, external collaborations, licensing deals and strategic acquisitions to expand its pipeline and commercial reach. Biogen is governed by an executive leadership team and a board of directors responsible for setting corporate strategy and overseeing its global operations.AI Generated. May Contain Errors. Read More Biogen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreBIIB MarketRank™: Biogen scored higher than 75% of companies evaluated by MarketBeat, and ranked 195th out of 840 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingModerate Buy Consensus RatingBiogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 1 strong buy rating, 17 buy ratings, 11 hold ratings, and 2 sell ratings.Upside PotentialBiogen has a consensus price target of $220.04, representing about 10.0% upside from its current price of $199.95.Amount of Analyst CoverageBiogen has been the subject of 22 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Biogen's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth20.82% Earnings GrowthEarnings for Biogen are expected to grow by 20.82% in the coming year, from $13.45 to $16.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biogen is 21.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.02.Price to Earnings Ratio vs. SectorThe P/E ratio of Biogen is 21.45, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.10.Price to Book Value per Share RatioBiogen has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Biogen's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.89% of the float of Biogen has been sold short.Short Interest Ratio / Days to CoverBiogen has a short interest ratio ("days to cover") of 4.14.Change versus previous monthShort interest in Biogen has recently increased by 10.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiogen does not currently pay a dividend.Dividend GrowthBiogen does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.75 News SentimentBiogen has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 46 news articles for Biogen this week, compared to 13 articles on an average week.Search Interest29 people have searched for BIIB on MarketBeat in the last 30 days. This is an increase of 107% compared to the previous 30 days.MarketBeat Follows15 people have added Biogen to their MarketBeat watchlist in the last 30 days. This is an increase of 275% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biogen insiders have not sold or bought any company stock.Percentage Held by Insiders0.25% of the stock of Biogen is held by insiders.Percentage Held by Institutions87.93% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biogen's insider trading history. Receive BIIB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIIB Stock News HeadlinesVERAXA Biotech Shows Regulatory Progress on Cancer Therapy PlatformJuly 20 at 1:17 PM | finance.yahoo.comBiogen, Bloom, First Solar, Oklo, NNE Trending With AnalystsJuly 18 at 5:10 AM | tipranks.comI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had written off. The stock climbed more than 1,100% over the next 3-4 years, with some subscribers reporting gains of $141,000, $272,000, or more. He believes a similar setup is forming now around what he calls the 'Energy Cube' - a compact nuclear system roughly the size of a shipping container, capable of powering up to 1,000 homes with no emissions, 24 hours a day. Bill Gates, Jeff Bezos, Google, and Microsoft have all backed companies in this space. The Nuclear Regulatory Commission is expected to issue a key approval as early as August - the first of its kind for this technology class in over a decade.July 20 at 1:00 AM | Monument Traders Alliance (Ad)Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA) and Biogen (BIIB)July 16, 2026 | theglobeandmail.comSlate Medicines Appoints Mark W. Hahn to Board of DirectorsJuly 16, 2026 | finance.yahoo.comSynapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology NationwideJuly 16, 2026 | finance.yahoo.comSynapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology NationwideJuly 16, 2026 | prnewswire.comRoche/ Biogen kidney drug granted FDA priority review for label expansionJuly 15, 2026 | seekingalpha.comSee More Headlines BIIB Stock Analysis - Frequently Asked Questions How have BIIB shares performed this year? Biogen's stock was trading at $175.99 at the beginning of 2026. Since then, BIIB stock has increased by 13.6% and is now trading at $199.95. How were Biogen's earnings last quarter? Biogen Inc. (NASDAQ:BIIB) released its earnings results on Wednesday, April, 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping the consensus estimate of $2.95 by $0.62. The company's quarterly revenue was up 1.9% on a year-over-year basis. Read the conference call transcript. Does Biogen have any subsidiaries? Biogen subsidiaries include these companies: Nightstar Therapeutics plc, Convergence Pharmaceuticals, TYSABRI, Stromedix Inc., Panima Pharmaceuticals AG, Syntonix Pharmaceuticals Inc., Fumapharm, and more. Who are Biogen's major shareholders? Biogen's top institutional shareholders include Handelsbanken Fonder AB (0.06%), Contravisory Investment Management Inc. (0.03%), Czech National Bank (0.03%) and Insight Wealth Strategies LLC (0.02%). Insiders that own company stock include Eric K Rowinsky, Nicole Murphy, Stephen A Sherwin, Stephen A Sherwin, Stephen A Sherwin, Priya Singhal and Rachid Izzar. View institutional ownership trends. How do I buy shares of Biogen? Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biogen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biogen investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), Broadcom (AVGO) and Intel (INTC). Company Calendar Last Earnings4/29/2026Today7/20/2026Next Earnings (Estimated)7/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 BIIB's financial health is in the Green zone, according to TradeSmith. BIIB has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:BIIB CIK875045 Webwww.biogen.com Phone(617) 679-2000Fax617-679-2617Employees7,500Year Founded1978Price Target and Rating Average Price Target for Biogen$220.04 High Price Target$300.00 Low Price Target$157.00 Potential Upside/Downside+10.0%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage31 Analysts Profitability EPS (Trailing Twelve Months)$9.32 Trailing P/E Ratio21.45 Forward P/E Ratio14.87 P/E GrowthN/ANet Income$1.29 billion Net Margins13.81% Pretax Margin16.33% Return on Equity12.83% Return on Assets8.01% Debt Debt-to-Equity Ratio0.34 Current Ratio3.06 Quick Ratio2.41 Sales & Book Value Annual Sales$9.94 billion Price / Sales2.97 Cash Flow$21.97 per share Price / Cash Flow9.10 Book Value$124.45 per share Price / Book1.61Miscellaneous Outstanding Shares147,637,000Free Float147,268,000Market Cap$29.52 billion OptionableOptionable Beta0.16 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:BIIB) was last updated on 7/20/2026 by MarketBeat.com Staff. From Our PartnersBacked Company Could Save Power GridA small Colorado company holds the rights to technology that could protect the U.S. public power grid from col...Altimetry | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | SponsoredNVIDIA offered $40B. The answer was no.Apple, NVIDIA, Google, Amazon, and Samsung all pay one company billions in royalties every year. NVIDIA tried ...Behind the Markets | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredTrump is positioned. Elon lights the fuse.Earlier this year, the Trump-backed World Liberty Trust applied for a federal banking charter. Now, new report...Crypto 101 Media | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
